GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (STU:NG9) » Definitions » YoY EPS Growth

NeoGenomics (STU:NG9) YoY EPS Growth : 17.17% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is NeoGenomics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. NeoGenomics's YoY EPS Growth for the quarter that ended in Mar. 2024 was 17.17%.

NeoGenomics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €-0.19.

NeoGenomics YoY EPS Growth Historical Data

The historical data trend for NeoGenomics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics YoY EPS Growth Chart

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.13 -54.17 -287.88 -1,666.13 41.37

NeoGenomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.81 33.96 53.47 40.59 17.17

NeoGenomics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

NeoGenomics's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-0.642--1.095)/ | -1.095 |
=41.37 %

NeoGenomics's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EPS Growth (Q: Mar. 2024 )
=(Earnings per Share (Diluted) (Q: Mar. 2024 )-Earnings per Share (Diluted) (Q: Mar. 2023 )) / | Earnings per Share (Diluted) (Q: Mar. 2023 )) |
=(-0.193--0.233)/ | -0.233 |
=17.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of NeoGenomics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

NeoGenomics (STU:NG9) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (STU:NG9) » Definitions » YoY EPS Growth
Comparable Companies
VCYT MYGN TWST OPK LAB CDNA NEOG CSTL FLGT GH TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN
Traded in Other Exchanges
NEO:USA
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
Website
https://www.neogenomics.com
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.

NeoGenomics (STU:NG9) Headlines

No Headlines